Snakebite drug drives BTG sales

BTG, a specialist healthcare company, has produced good interims driven partly by sales of its speciality pharmaceuticals, which pushed up sales and profits. It also served notice that it is likely to meet or beat consensus forecasts and is on the hunt for further acquisitions.

BTG, a specialist healthcare company, has produced good interims driven partly by sales of its speciality pharmaceuticals, which pushed up sales and profits. It also served notice that it is likely to meet or beat consensus forecasts and is on the hunt for further acquisitions.

Chief Executive, Louise Makin commented: "Over the full year, revenues are expected to be in the range £205m to £215m. The group expects to generate significant cash to enable continued investment in development and acquisition activities, and BTG remains very well placed to continue to execute its growth strategy."

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.